Mizuho restated their top pick rating on shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) in a research report released on Wednesday. Mizuho currently has a $26.00 price target on the specialty pharmaceutical company’s stock.

“We continue to like ADMS into its August 24 PDUFA for Parkinson’s Disease, and we reiterate our Buy rating and our $26 PT.”,” Mizuho’s analyst commented.

Separately, Zacks Investment Research upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, February 28th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $28.43.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals (NASDAQ:ADMS) opened at 17.69 on Wednesday. The stock’s market capitalization is $393.05 million. The firm’s 50-day moving average price is $16.99 and its 200 day moving average price is $16.17. Adamas Pharmaceuticals has a 12-month low of $12.07 and a 12-month high of $19.50.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings results on Tuesday, February 21st. The specialty pharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.12. The business earned $0.04 million during the quarter, compared to analyst estimates of $0.17 million. Adamas Pharmaceuticals had a negative return on equity of 38.31% and a negative net margin of 5,267.99%. The business’s revenue was down 92.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.58) earnings per share. On average, equities analysts anticipate that Adamas Pharmaceuticals will post ($3.26) EPS for the current year.

Your IP Address:

Several large investors have recently bought and sold shares of the stock. Citadel Advisors LLC bought a new stake in Adamas Pharmaceuticals during the third quarter worth about $219,000. Ardsley Advisory Partners bought a new stake in Adamas Pharmaceuticals during the third quarter worth about $246,000. GAM Holding AG bought a new stake in Adamas Pharmaceuticals during the third quarter worth about $328,000. Russell Investments Group Ltd. bought a new stake in Adamas Pharmaceuticals during the fourth quarter worth about $469,000. Finally, Opus Point Partners Management LLC raised its stake in Adamas Pharmaceuticals by 32.7% in the third quarter. Opus Point Partners Management LLC now owns 60,000 shares of the specialty pharmaceutical company’s stock worth $985,000 after buying an additional 14,802 shares during the period. Institutional investors and hedge funds own 75.44% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

5 Day Chart for NASDAQ:ADMS

Receive News & Ratings for Adamas Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.